Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2005-02-03
2010-12-28
Skowronek, Karlheinz R (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C600S322000
Reexamination Certificate
active
07860656
ABSTRACT:
The present invention is drawn to a new diagnosis method for detecting the extent of hepatic steatosis in a patient, in particular in a patient who suffers from a disease involving hepatic steatosis, or who already had a positive diagnosis test of liver fibrosis and/or presence of liver necroinflammatory lesions, by using the serum concentration of easily detectable biological markers. The invention is also drawn to diagnosis kits for the implementation of the method.
REFERENCES:
patent: 6631330 (2003-10-01), Poynard
patent: 2006/0172286 (2006-08-01), Poynard
Day et al. (Hepatology, p. 1463-1466, Jun. 1998).
Rinella et al. (Liver Transplantation, vol. 7, No. 5, p. 409-414, May 2001).
Burt (Current Diagnostic Pathology, vol. 7, p. 141-147, 2001).
Lu et al. (world Journal of Gastroenterology, vol. 9, No. 3, p. 2796-2800, 2003).
Chitturi et al. (Hepatology, vol. 36, No. 2, p. 403-409, 2002).
Chan et al. (International Journal of Obesity, vol. 28, 1257-1263, 2004).
Duhamel et al. (Hepatology, vol. 4, No. 4, p. 577-585, 1984).
Koruk et al. (Turkish journal of Gastroenterology, vol. 14, No. 1, p. 12-17, 2003).
AASLD Abstracts,Hepatology, 34:4 Suppl., October, 510A-511A (2003).
Angulo, “Nonalcoholic Fatty Liver Disease,”N Engl J Med, vol. 346, No. 16, 1221-1231 (Apr. 18, 2002).
Bellentani et al., “Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy,”Ann Intern Med, 132(2):112-117 (2000).
Bravo et al., “Liver Biopsy,”N Engl J Med, 344(7):495-500 (2001).
Browning et al., “Molecular mediators of hepatic steatosis and liver injury,”J Clin Invest, 114(2):147-152 (2004).
Callewaert et al., “Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics,”Nat Med, 10(4):429-434 (2004).
Dam-Larsen et al., “Long term prognosis of fatty liver: risk of chronic liver disease and death,”Gut, 53(5):750-755 (2004).
Day, “Pathogenesis of steatohepatitis,”Best Pract Res Clin Gastroenterol, 16(5):663-678 (2002).
El-Serag et al., “Diabetes Increases the Risk of Chronic Liver Disease and Hepatocellular Carcinoma,”Gastroenterology, 126(2):460-468 (2004).
Fabris et al., “Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C,”J Hepatol, 41(4):644-651 (2004).
Imbert-Bismut et al., “Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors,”Clin Chem Lab Med, 42(3):323-333 (2004).
Levitsky et al., “Diagnosis and Therapy of Alcoholic Liver Disease,”Seminars in Liver Dis, 24(3):233-247 (2004).
Munteanu et al., Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest),Comparative Hepatology, 3:3 (2004).
Myers et al., “Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B,”Journal of Hepatology, 39(2):222-230 (2003).
Naveau et al., “Biomarkers for the Prediction of Liver Fibrosis in Patients With Chronic Alcoholic Liver Disease,”Clin Gastroenterol and Hepatol, 3(2):167-174 (2005).
Phillips et al., “Post-transplant Recurrent Hepatitis B Viral Liver Disease; Viral-burden, Steatoviral, and Fibroviral Hepatitis B,”Am Journal of Pathol,140(6):1295-1308 (1992).
Poynard et al., “Effect of Treatment With Peginterferon or Interferon Alfa-2b and Ribavirin on Steatosis in Patients Infected With Hepatitis C,”Hepatology, 38(1):75-85 (2003).
Poynard et al., “Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C,”Comp Hepatol, 3(1):8 (2004).
Poynard et al., “Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C,”Clin Chem, 50:8 1344-1355 (2004).
Sørensen et al., “Prospective Evaluation of Alcohol Abuse And Alcoholic Liver Injury in Men As Predictors Of Development Of Cirrhosis,”The Lancet, 2(8397):241-244 (1984).
Angulo, “Nonalcoholic Fatty Liver Disease,”N Engl J Med, 346(16):1221-1231 (2002).
Annoni et al., “Serum Type III Procollagen Peptide and Laminin (Lam-P1) Detect Alcoholic Hepatitis in Chronic Alcohol Abusers,”Hepatology, 9(5):693-697 (1989).
Bedossa et al., “Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients,”Alcohol Clin Exp Res, 12(1):173-178 (1988).
Bellentani et al., “Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy,”Ann Intern Med, 132(2):112-117 (2000).
Castera et al., “Serum Laminin and Type IV Collagen are Accurate Markers of Histologically Severe Alcoholic Hepatitis in Patients with Cirrhosis,”J Hepatol, 32(3):412-418 (2000).
Chossegros, “Extracellular Martix Serum Markers (ECMSM) in Alcoholic Liver Disease,”J Hepatol, 22(2):96-99 (1995).
Halfon et al., “A Prospective Assessment of the Inter-Laboratory Variability of Biochemical Markers of Fibrosis (Fibro Test) and Activity (ActiTest) in Patients with Chronic Liver Disease,”Comparative Hepatology, 1(3):1-10 (2002).
Maher, “Alcoholic Steatosis and Steatohepatitis,”Seminars in Gastrointest Dis, 13(1):31-39 (2002).
Mathurin et al., “Survival and Prognostic Factors in Patients with Severe Alcoholic Hepatitis Treated with Prednisolone,”Gastroenterology, 110(6):1847-1853 (1996).
Mathurin et al., “Corticosteroids Improve Short-Term Survival in Patients with Severe Alcoholic Hepatitis (AH): Individual Data Analysis of the Last Three Randomized Placebo Controlled Double Blind Trials of Corticosteroids in Severe AH,”Journal of Hepatology, 36(4):480-487 (2002).
Nøjgaard et al., “Serum Levels of YKL-40 and PIIINP as Prognostic Markers in Patients with Alcoholic Liver Disease”,Journal of Hepatology, 39(2):179-186 (2003).
Naveau et al., “Alpha-2-Macroglobulin and Hepatic Fibrosis,”Digestive Disease and Sciences, 39(1):2426-2432 (1994).
Poynard et al., “The Diagnostic Value of Biomarkers (SteatoTest) for the Prediction of Liver Steatosis,”Comparative Hepatology, 4(10):1-14 (2005).
Poynard et al., “Evaluation of Efficacy of Liver Transplantation in Alcoholic Cirrhosis Using Matched and Simulated Controls: 5 Year Survival,”Journal of Hepatology, 30:1130-1137 (1999).
Browning et al., “Molecular Mediators of Hepatic Steatosis and Liver Injury,”The Journal of Clinical Investigation, 114(2): 147-152 (2004).
Munteanu et al., “Noninvasive Biomarkers for the Screening of Fibrosis, Steatosis and Steatohepatitis in Patients with Metabolic Risk Factors: Fibro Test-FibroMax™ Experience,”J Gastrointestin Liver Dis,17(2): 187-191 (2008).
Poynard et al., “The Diagnostic Value of Biomarkers (SteatoTest) for the Prediction of Liver Steatosis,”Comparative Hepatology, 4(10): 1476-5926 (2005).
U.S. Appl. No. 11/050,638, filed Feb. 3, 2005, Poynard, Request for Continued Examination and Response to Office Action, Mar. 31, 2010.
U.S. Appl. No. 11/050,638, filed Feb. 3, 2005, Poynard, Notice of Appeal, Feb. 3, 2010.
U.S. Appl. No. 11/050,638, filed Feb. 3, 2005, Poynard, Advisory Action, Nov. 24, 2009.
U.S. Appl. No. 11/050,638, filed Feb. 3, 2005, Poynard, Response to Final Office Action, Nov. 2, 2009.
Assistance Publique-Hopitaux de Paris (Ap-Hp)
Ballard Spahr LLP
Skowronek Karlheinz R
LandOfFree
Diagnosis method of hepatic steatosis using biochemical markers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis method of hepatic steatosis using biochemical markers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis method of hepatic steatosis using biochemical markers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4203324